The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Vernon Bernardino - HC Wainwright - Analyst
: Hi. Thanks for taking my question. And Steve and Seth, welcome aboard. Looking forward to catching up to you in-person in the near future.
Regarding the repatriated NRX-101 drug supply, just wondering if you could go to the mechanics or perhaps a history of that process, and what
was the situation before that repatriation?
Question: Vernon Bernardino - HC Wainwright - Analyst
: Hi, Robert.
Question: Vernon Bernardino - HC Wainwright - Analyst
: And as far as that was a desire to control the supply because of (inaudible) shipping --
Question: Vernon Bernardino - HC Wainwright - Analyst
: Okay. (inaudible)
Question: Vernon Bernardino - HC Wainwright - Analyst
: Okay. Maybe this is for Seth. Is there any accounting considerations as far as that supplies location that needs to be considered?
Question: Vernon Bernardino - HC Wainwright - Analyst
: Okay. One more question, and then I'll give -- one more question and then that's all I have, if I could. Regarding the supply of ZYESAMI, is there any
accounting considerations that you're looking at there, considering there may, at least in my opinion, a possible impairment if future studies aren't
pursued?
Question: Vernon Bernardino - HC Wainwright - Analyst
: Sorry, if I was just me-mumbling. But is there any accounting consideration as far as the supply of ZYESAMI that you may be considering, considering
that -- in light that you may not pursue further future studies with ZYESAMI?
Question: Vernon Bernardino - HC Wainwright - Analyst
: Okay. Thanks for taking my question and congrats and looking forward to seeing the whole team in the near future.
| 
